| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001064008A3 Vaccine for the treatment of artherosclerosis |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 02/14/2002 | WO2001058921A3 Methods and compositions for generating angiostatin |
| 02/14/2002 | WO2001051619A3 Genetically modified fibroblast cell |
| 02/14/2002 | WO2001049274A3 Methods for pulmonary delivery of interleukin-2 |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | WO2001041750A3 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 02/14/2002 | WO2001037852A3 Methods of inhibiting atrophy or promoting hypertrophy |
| 02/14/2002 | WO2001034137A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2000067698A3 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | WO2000044908A9 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | WO1995029669A3 Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019540 Conformationally constrained compounds as pharmaceutical agents |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019533 Piperidine derivatives and anti-platelet agents containing the same |
| 02/14/2002 | US20020019530 Antitumor agent |
| 02/14/2002 | US20020019525 Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands |
| 02/14/2002 | US20020019438 Respiratory system disorders |
| 02/14/2002 | US20020019425 Anticancer agents; administering p53 gene or protein |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019418 Methods of preventing breast cancer |
| 02/14/2002 | US20020019416 Esters and amides as pla2 inhibitors |
| 02/14/2002 | US20020019414 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 02/14/2002 | US20020019413 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019404 Anticancer agents, skin disorders |
| 02/14/2002 | US20020019403 Inhibit amyloid protein deposits |
| 02/14/2002 | US20020019401 Psychological disorders; adjustment of dopamine concentration |
| 02/14/2002 | US20020019397 Heterocycle carboxamides as antiviral agents |
| 02/14/2002 | US20020019392 By administering indole compounds such as 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 02/14/2002 | US20020019386 5-HT4 receptor antagonists |
| 02/14/2002 | US20020019382 Curcumin analogs with anti-tumor and anti-angiogenic properties |
| 02/14/2002 | US20020019367 Compositions and methods for modulation of vascular structure and/or function |
| 02/14/2002 | US20020019363 Viricides for hepatitis c |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019357 Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 02/14/2002 | US20020019351 Treatment of skeletal disorders |
| 02/14/2002 | US20020019043 Treating inflammatory bowel disease in humans; obtain human, administer drug, monitor for reduction in side effects from gastrointestinal disorder |
| 02/14/2002 | US20020019028 Peptide; for use in the treatment of defects associated with polypeptide transfer |
| 02/14/2002 | US20020018818 Plant extract; boiling extraction |
| 02/14/2002 | US20020018812 Sponge-like or foam |
| 02/14/2002 | DE10035991A1 Nagellackzusammensetzung Nail polish composition |
| 02/14/2002 | CA2774959A1 Method of using diketopiperazines and composition containing them |
| 02/14/2002 | CA2634715A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy}-11.beta.-hydroxy-16.alpha-methyl-3-oxo-androsta-1,4-diene-17.beta.carbothioic acids-fluoromethyl ester as an anti-inflammatory agent |
| 02/14/2002 | CA2420967A1 Heterocyclic compounds as ligands of the gabaa receptor |
| 02/14/2002 | CA2420066A1 Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 02/14/2002 | CA2419062A1 Methods for culturing human lung mast cells and uses thereof |
| 02/14/2002 | CA2419060A1 Indole compounds useful for the treatment of cancer |
| 02/14/2002 | CA2419044A1 Macrolide antibiotics |
| 02/14/2002 | CA2419042A1 Medicine for fighting against sexual dysfunction |
| 02/14/2002 | CA2419036A1 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/14/2002 | CA2419030A1 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418946A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | CA2418915A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2418904A1 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 02/14/2002 | CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | CA2418832A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418386A1 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | CA2418369A1 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 02/14/2002 | CA2418353A1 Parenteral vaccine formulations and uses thereof |
| 02/14/2002 | CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | CA2417994A1 Synthetic salicylihalamides, apicularens and derivatives thereof |
| 02/14/2002 | CA2417967A1 Azabicyclic derivatives and their therapeutic use |
| 02/14/2002 | CA2417914A1 Cyclic oxyguanidine protease inhibitors |
| 02/14/2002 | CA2417826A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 02/14/2002 | CA2417784A1 Pyrrolotriazolopyrimidinone derivatives |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | CA2417676A1 Sequences for integrin alpha-8 |
| 02/14/2002 | CA2417606A1 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417368A1 Suppressor gene |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2416906A1 Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo[1,2-a]imidazol-2-one |
| 02/14/2002 | CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415469A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | CA2411928A1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases |
| 02/14/2002 | CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | CA2386725A1 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/13/2002 | EP1179541A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 02/13/2002 | EP1179529A1 Novel hydroxamic acid derivatives |
| 02/13/2002 | EP1179344A1 Release-regulating preparations |
| 02/13/2002 | EP1179343A1 Remedies for diabetes |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |